Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Osteosarcoma × penpulimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Rectal Neoplasms 1 Pancreatic Adenocarcinoma Metastatic 1 Osteosarcoma 1 Gastrointestinal Neoplasms 1 Gastrointestinal Diseases 1 Digestive System Diseases 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Carcinoma 1 Advanced Solid Tumor 1 Advanced Pancreatic Cancer 1

Interventions

fludarabine 5 Cyclophosphamide 5 Temozolomide 4 cabozantinib 3 Zoledronic Acid 3 Gemcitabine 3 Doxorubicin 3 irinotecan sucrosofate 2 atezolizumab 2 Vincristine 2 Sunitinib 2 Specimen Handling 2 Radiosurgery 2 Methotrexate 2 Irinotecan 2 Ifosfamide 2 Disulfiram 2 Cisplatin 2 Biopsy 2 vactosertib 1 trametinib 1 talazoparib 1 surufatinib 1 silmitasertib 1 selinexor 1 regorafenib 1 penpulimab 1 pegylated granulocyte colony-stimulating factor 1 pegfilgrastim 1 pazopanib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06114225 2023-11-02

PROMIS

Ruijin Hospital

Phase 2 Recruiting

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡